FARA is pleased to share news that one of our gene therapy partners, Agilis Biotherapeutics, has been acquired by PTC Therapeutics. PTC Therapeutics will bring expertise in rare disease drug development and additional resources to advance the work that Agilis has initiated in FA gene therapy. We are looking forward working with PTC Therapeutics to accelerate this important FA program.
Read the entire article HERE
